Compare · LLY vs ZGNX
LLY vs ZGNX
Side-by-side comparison of Eli Lilly and Company (LLY) and Zogenix Inc. (ZGNX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and ZGNX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY carries a market cap of $1.27T.
- LLY has hit the wire 45 times in the past 4 weeks while ZGNX has been quiet.
- LLY has more recent analyst coverage (25 ratings vs 6 for ZGNX).
- Company
- Eli Lilly and Company
- Zogenix Inc.
- Price
- $1348.33-0.23%
- -
- Market cap
- $1.27T
- -
- 1M return
- +3.16%
- -
- 1Y return
- +27.28%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2010
- News (4w)
- 45
- 0
- Recent ratings
- 25
- 6
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Zogenix Inc.
Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.
Latest LLY
- Gold, Silver and Crude Slide Hard as Volatility Jumps on the Week
- Director Jamere Jackson was granted 168 shares, increasing direct ownership by 2% to 9,861 units (SEC Form 4)
- Director Jon R Moeller was granted 168 shares, increasing direct ownership by 55% to 473 units (SEC Form 4)
- Director William G Kaelin Jr was granted 168 shares, increasing direct ownership by 0.76% to 22,139 units (SEC Form 4)
- Director Kimberly H Johnson was granted 168 shares, increasing direct ownership by 5% to 3,452 units (SEC Form 4)
- Director Carolyn R Bertozzi was granted 178 shares, increasing direct ownership by 9% to 2,178 units (SEC Form 4)
- Director Katherine Baicker was granted 168 shares, increasing direct ownership by 0.71% to 23,815 units (SEC Form 4)
- Director Mary Lynne Hedley was granted 168 shares, increasing direct ownership by 7% to 2,430 units (SEC Form 4)
- Director Gabrielle Sulzberger was granted 171 shares, increasing direct ownership by 6% to 3,188 units (SEC Form 4)
- Director Juan R Luciano was granted 179 shares, increasing direct ownership by 1% to 17,148 units (SEC Form 4)
Latest ZGNX
- ReAlta Life Sciences Announces Appointment of Jonathan Rigby to Board of Directors
- FDA Approval for FINTEPLA issued to ZOGENIX INC
- FDA Approval for FINTEPLA issued to ZOGENIX INC
- FDA Approval for FINTEPLA issued to ZOGENIX INC
- FDA Approval for FINTEPLA issued to ZOGENIX INC
- FDA Approval for FINTEPLA issued to ZOGENIX INC
- FDA Approval for FINTEPLA issued to ZOGENIX INC
- The Daily Biotech Pulse: MEI Pharma Wilts On Adverse Regulatory Development, Decision Day For Zogenix, AN2 Therapeutics IPO
- Benzinga Pro's Top 5 Stocks To Watch For Monday, Mar. 21, 2022: BA, COIN, NILE, ZGNX, MULN
- The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings